目的 · 制备细菌外膜囊泡(outer membrane vesicle,OMV)包覆的载卵清蛋白(ovalbumin,OVA)聚乳酸 - 羟基乙酸共聚
物 [poly (lactic-co-glycolic acid) copolymer,PLGA] 纳米载体并用于小鼠鼻腔免疫效果评价。方法 · 采用超滤离心法制备 OMV,采用
乳化溶剂挥发法制备包载 OVA 的 PLGA 纳米粒(nanoparticle,NP),采用机械挤出法制备 OMV 包覆的 PLGA 载药 NP,并对其进行
表征。载 OVA 的 OMV-PLGA NP 经 BALB/c 小鼠鼻腔给药,用 ELISA 法检测鼻腔灌洗液、空肠黏膜和粪便中特异性 sIgA 抗体水平。
结果 · OMV 包覆的 PLGA 载药 NP 粒径为 (234.4±22.9) nm,透射电子显微镜观察其具有核壳结构。给药 14 d 后,载 OVA 的 OMV-PLGA
NP 给药组在鼻腔灌洗液、空肠黏膜及粪便中 sIgA 抗体水平最高;与 OMV+OVA 给药组相比,载 OVA 的 OMV-PLGA NP 给药组在鼻
腔灌洗液、空肠黏膜及粪便中的 OVA 特异性 sIgA 抗体水平分别提高了 1.6、2.1 和 1.7 倍,OMV 特异性 sIgA 抗体水平均提高了 1.5 倍。
结论 · 该纳米给药系统能同时使 OMV 和 OVA 被摄取与呈递,产生较强的小鼠黏膜免疫诱导反应。
] Objective · To prepare a bacterial outer membrane vesicle (OMV) coated poly (lactic-co-glycolic acid) copolymer (PLGA) nanoparticle
loaded with ovalbumin (OVA) and evaluate its intranasal immune effect in mice. Methods · OMV was prepared by ultrafiltration concentration method.
OVA loaded PLGA nanoparticle (NP) was prepared by emulsion-solvent evaporation method. OMV coated PLGA nanoparticle (OMV-PLGA NP) loaded
with OVA was prepared by extrusion method and characterized. BALB/c mice were intranasally immunized and specific sIgA levels in nasal wash,
jejunum and fecal pellet were determined by ELISA. Results · Size of OVA loaded OMV-PLGA NP was (234.4±22.9) nm. The shell-core structure of
OVA loaded OMV-PLGA NP was proved by transmission electron microscope. After 14 d of administration, sIgA antibody levels in nasal wash, jejunum
and fecal pellet of OVA loaded OMV-PLGA NP treated group were the highest in all treated groups. Compared with the group treated with OMV and
OVA, OVA-specific sIgA antibody level in nasal wash, jejunum and fecal pellet of OVA loaded OMV-PLGA NP treated group was increased 1.6, 2.1 and
1.7 times, respectively. Compared with the group treated with OMV and OVA, OMV-specific sIgA antibody level in nasal wash, jejunum and fecal pellet
of OVA loaded OMV-PLGA NP treated group was all increased 1.5 times. Conclusion · This novel nanoparticle drug delivery system can simultaneously
delivery OVA and OMV to antigen presenting cells, resulting in stronger mucosal immune response in mice.